Home 禄 Business 禄 Manufacturing
Shanghai drug maker denies notice of probe
Source: Bloomberg News |
00:15 UTC+8 May 24, 2012
|
Print Edition
Print Edition
SHANGHAI Pharmaceuticals Holding Co hasn't received any notice of a probe by regulators in Chinese mainland or Hong Kong, the company said yesterday in a response to a newspaper report that had caused its shares to plunge.
The company complied with rules in making acquisitions, and its accounts and those of its units comply with standards, it said in a Hong Kong stock exchange filing yesterday. The stock dropped 24 percent in Hong Kong yesterday, the biggest decline since its May 2011 debut. In Shanghai, the shares fell 10 percent, the exchange-imposed daily limit.
The 21st Century Business Herald reported yesterday that Shanghai Pharma is being investigated by the Hong Kong stock exchange and China Securities Regulatory Commission for suspected financial fraud involving two acquisitions earlier this year, citing a company executive it didn't identify.
Shanghai Pharma said it completed the acquisition of 70 percent of Changzhou Kony Pharma Co, and the consolidation of Kony's accounts into its first-quarter report met standards. The acquisition of the intangible assets of Shanghai Asia Pioneer Pharmaceutical Co is "fair and reasonable" and complies with regulatory requirements, Shanghai Pharma said.
The company complied with rules in making acquisitions, and its accounts and those of its units comply with standards, it said in a Hong Kong stock exchange filing yesterday. The stock dropped 24 percent in Hong Kong yesterday, the biggest decline since its May 2011 debut. In Shanghai, the shares fell 10 percent, the exchange-imposed daily limit.
The 21st Century Business Herald reported yesterday that Shanghai Pharma is being investigated by the Hong Kong stock exchange and China Securities Regulatory Commission for suspected financial fraud involving two acquisitions earlier this year, citing a company executive it didn't identify.
Shanghai Pharma said it completed the acquisition of 70 percent of Changzhou Kony Pharma Co, and the consolidation of Kony's accounts into its first-quarter report met standards. The acquisition of the intangible assets of Shanghai Asia Pioneer Pharmaceutical Co is "fair and reasonable" and complies with regulatory requirements, Shanghai Pharma said.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
